---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-030205"
form_type: "8-K"
ticker: "EXOZ"
cik: "0002010788"
company_name: "EXOZYMES INC."
filed_at: "2026-06-25T23:36:23+00:00"
generated_at: "2026-06-26T10:05:26.876722+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# eXoZymes receives $2M NIH Phase IIB SBIR grant for cannabinoid analog drug discovery

## Summary
- NIH NIGMS Phase IIB SBIR grant of $2,028,518 to support development of rare cannabinoids and engineered analogs.
- Work on two-year grant begins July 1, 2026; total non-dilutive funding now ~$19.7M.
- Grant adds a second biosolution to eXoZymes' pipeline after NCT, targeting pharmaceutical partnerships.
- U.S. minor cannabinoids market forecast to grow from $11.5B (2023) to $33.3B (2030) at ~15% CAGR.

## SEC filing metadata
- accession: 0001493152-26-030205
- form_type: 8-K
- ticker: EXOZ
- cik: 0002010788
- company_name: EXOZYMES INC.
- filed_at: 2026-06-25T23:36:23+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2010788/000149315226030205/0001493152-26-030205-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2010788/000149315226030205/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-030205
- JSON: https://secwatch.observer/filing/0001493152-26-030205.json
- Plain text: https://secwatch.observer/filing/0001493152-26-030205.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.